Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System Workshop Summary (2011) / Chapter Skim
Currently Skimming:
Appendix C: Agenda
Appendix C: Agenda
Pages 49-62
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 49... ...
The goal of the workshop is to present promising current and emerging technologies with potential as reliable glutamate biomarkers, and to outline strategies to accelerate development, validation, and implementation of these biomarkers as powerful tools to advance drug development for nervous system disorders associated with glutamatergic dysfunction. Meeting Objectives: • B riefly outline the need for glutamate-related biomarkers both for understanding the causes of neuropsychiatric disorders and neuro degenerative diseases associated with glutamatergic dysfunction, and for accelerating drug development for these disorders.
|
From page 50... ...
June 21: Keck Center Room 100 1:00 p.m. Welcome, Introductions, and Workshop Objectives Chi-Ming Lee, Workshop Cochair Executive Director of Translational Science AstraZeneca Pharmaceuticals Daniel Javitt, Workshop Cochair Program Director Cognitive Neuroscience and Schizophrenia Nathan Kline Institute 1:10 p.m.
|
From page 51... ...
: Glutamate Dysfunction, Treatments, and Need for Glutamate Biomarkers Carlos Zarate Chief of the Mood and Anxiety Disorders Research Unit Associate Clinical Director of the Laboratory of Molecular Pathophysiology NIMH, NIH 2:15 p.m. Autism Spectrum Disorders: Glutamate Dysfunction, Treatments, and Need for Glutamate Biomarkers Mark Bear Picower Professor of Neuroscience Department of Brain and Cognitive Sciences Massachusetts Institute of Technology Scientific Founder, Seaside Therapeutics
|
From page 52... ...
Drug Addiction: Glutamate Dysfunction, Treatments, and Need for Glutamate Biomarkers Peter Kalivas Co-Chair, Department of Neurosciences Medical University of South Carolina 3:30 p.m. Stroke and Ischemia: Glutamate Dysfunction, Treatments, and Need for Glutamate Biomarkers Dennis Choi Vice-President for Academic Health Affairs Woodruff Health Sciences Center Executive Director of the Strategic Neurosciences Initiative Emory University
|
From page 53... ...
Discussion with Panelists and Attendees Chi-Ming Lee, Workshop Cochair Executive Director of Translational Science AstraZeneca Pharmaceuticals Daniel Javitt, Workshop Cochair Program Director Cognitive Neuroscience and Schizophrenia Nathan Kline Institute 5:00 p.m. ADJOURN June 22: Keck Center Room 100 SESSION II: CURRENT AND EMERGING TECHNOLOGIES TO ASSESS GLUTAMATERGIC FUNCTION Session Objectives: • iscuss current and emerging technologies and associated analyti D cal methods for assessing glutamatergic function, their specificity for the glutamate system, their potential for translation into clinical biomarkers, and their validation status.
|
From page 54... ...
9:00 a.m. Welcome and Review of Day One Chi-Ming Lee, Workshop Cochair Executive Director of Translational Science AstraZeneca Pharmaceuticals Daniel Javitt, Workshop Cochair Program Director Cognitive Neuroscience and Schizophrenia Nathan Kline Institute 9:10 a.m.
|
From page 55... ...
Cindy Yee-Bradbury Associate Professor Department of Psychology University of California–Los Angeles
|
From page 56... ...
; Functional MRI (fMRI) ; Gamma-Evoked Oscillations Angus MacDonald Associate Professor Department of Psychology University of Minnesota Hippocampal Function and Long-Term Potentiation (LTP)
|
From page 57... ...
Robert Innis Molecular Imaging Branch PET Neuroimaging Sciences Section NIMH, NIH An Integrated Imaging and Animal Models Approach to Identifying Schizophrenia Biomarkers Stephen Rayport Associate Professor of Clinical Neuroscience Department of Psychiatry Columbia University Medical Center Proton Magnetic Resonance Spectroscopy (MRS) Robert Mather Principal Scientist Pfizer Pharmaceuticals Pharmacogenomic and Epigenomic Markers (Disease-Specific)
|
From page 58... ...
3:15 p.m. Session Objectives and Introduction William Potter, Panel Chair Cochair Emeritus, Neuroscience Steering Committee, FNIH Biomarkers Consortium Former Vice President, Translational Neuroscience, Merck & Co., Inc.
|
From page 59... ...
Discussion with Speakers and Attendees William Potter, Panel Chair Cochair Emeritus, Neuroscience Steering Committee, FNIH Biomarkers Consortium Former Vice President, Translational Neuroscience, Merck & Co., Inc. SESSION IV: NEXT STEPS FOR ACCELERATING GLATAMATE BIOMARKER DEVELOPMENT AND QUALIFICATION Session Objectives: • iscuss the current barriers to biomarker development in academia D and industry.
|
From page 60... ...
Eli Lilly Panel Discussion: Dennis Choi Vice President for Academic Health Affairs Woodruff Health Sciences Center Executive Director of the Strategic Neurosciences Initiative Emory University Mark Bear Picower Professor of Neuroscience Department of Brain and Cognitive Sciences Massachusetts Institute of Technology Scientific Founder, Seaside Therapeutics Daniel Umbricht Lead, Neuroscience Translational Medicine Hoffmann-La Roche John Dunlop Senior Vice President and Chief Scientific Officer Neuroscience Research Unit Pfizer Stevin Zorn Executive Vice President, R&D Lundbeck
|
From page 61... ...
• hat partnerships are needed to accelerate glutamate biomarker W research and development for translational medicine? • hat are the next steps toward establishing research principles and W guidelines for qualification of glutamatergic biomarkers?
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.